Quick Answer
Neonatal phototherapy is a light-based treatment used to reduce elevated unconjugated bilirubin when a newborn’s bilirubin level reaches the appropriate treatment threshold. [1,2]
During phototherapy, therapeutic blue-to-green light is absorbed by bilirubin in the skin and triggers photochemical changes that convert bilirubin into photoisomers and other photoproducts that can be eliminated more readily from the body. [2]
The American Academy of Pediatrics (AAP) identifies approximately 460–490 nm as the relevant blue-to-green range, with an optimal peak around 478 nm. [2]
For intensive phototherapy in term infants, the AAP recommends an irradiance of at least approximately 30 µW/cm²/nm, while emphasizing that as much of the infant’s exposed body surface as practical should receive therapeutic light. [1,2]
For hospitals evaluating a neonatal phototherapy device, the most important considerations include spectral output, delivered irradiance, irradiance uniformity, illuminated body surface area, thermal management, safety, clinical evidence, reliability, and total cost of ownership.
What Is Newborn Jaundice?
Newborn jaundice, also called neonatal hyperbilirubinemia, occurs when bilirubin accumulates in the blood and tissues.
Bilirubin is produced naturally when red blood cells are broken down. Newborns can develop elevated unconjugated bilirubin because bilirubin production is relatively high while hepatic uptake, conjugation, and excretion are still developing. [1,2]
In many newborns, jaundice is temporary and resolves without intensive treatment. However, excessive unconjugated bilirubin can cross into the brain and contribute to acute bilirubin encephalopathy and, in severe cases, permanent neurological injury. [1,2]
For this reason, clinicians monitor bilirubin levels and determine whether treatment is indicated according to the infant’s age, gestational age, bilirubin concentration, rate of increase, and other risk factors. [1]
The 2022 AAP clinical practice guideline applies to newborn infants 35 weeks’ gestation or older and uses treatment thresholds based on these clinical factors. [1]
For a fuller picture of the care pathway, see NOVOS’s overview of newborn jaundice treatment.
When Does Newborn Jaundice Require Phototherapy?
The decision to start phototherapy is not based on the appearance of jaundice alone.
Clinical factors include:
- Gestational age
- Postnatal age in hours
- Total serum bilirubin (TSB)
- Rate of bilirubin increase
- Neurotoxicity risk factors
- Evidence of hemolysis or other underlying causes
- The infant’s overall clinical condition [1]
Phototherapy is therefore a clinical treatment rather than simply a cosmetic intervention to make the skin appear less yellow. The objective is to reduce bilirubin effectively and prevent progression toward levels associated with bilirubin neurotoxicity or escalation of care.
How Does Phototherapy Work?
Phototherapy uses light energy to change the molecular structure of bilirubin so it can be eliminated from the body.
- Light absorption. Bilirubin in the skin absorbs light at specific wavelengths in the blue-to-green range — approximately 460–490 nm, with an optimal peak around 478 nm. [2]
- Photochemical change. The absorbed light energy converts bilirubin into photoisomers and other photoproducts that are more water-soluble and can be excreted more readily. [2]
- Elimination. These converted forms are cleared via bile and urine, reducing the concentration of unconjugated bilirubin in the blood. [2]
Two factors drive clinical effectiveness:
- Irradiance — the intensity of therapeutic light reaching the skin at the effective wavelength (µW/cm²/nm).
- Illuminated body surface area — how much of the infant’s skin receives therapeutic light.
More effective light reaching more skin supports faster bilirubin reduction. [1,2]
Intensive Phototherapy vs. Standard Phototherapy
The AAP distinguishes between standard and intensive phototherapy. Intensive phototherapy uses adequate spectral irradiance (at least approximately 30 µW/cm²/nm in term infants) while exposing as much of the infant’s body surface as practical. [1,2]
- Standard phototherapy reduces bilirubin effectively for mild jaundice but may not be sufficient when bilirubin is rising toward treatment thresholds.
- Intensive phototherapy delivers higher effective irradiance over a larger body-surface area and is used when bilirubin is high and needs to be reduced quickly. [1,2]
The move toward intensive phototherapy reflects a strong clinical imperative: the faster bilirubin falls, the lower the risk of reaching a threshold that would require escalation of care, including exchange transfusion.
LED vs. Fluorescent Phototherapy: What Really Matters
Modern LED systems have largely replaced traditional fluorescent lamps for phototherapy. LED-based systems can provide:
- Precise spectral output — light engineered to the therapeutic blue-to-green wavelength range without unnecessary UV or infrared.
- Long operating life — LEDs typically last tens of thousands of hours, so output does not fade with age.
- Favorable thermal and maintenance characteristics — lower heat output in the light source and reduced lamp-replacement needs.
However, LED does not automatically mean clinically superior. A phototherapy device should be evaluated based on its complete configuration, including:
- Spectral output
- Delivered irradiance
- Irradiance uniformity
- Illuminated body surface area
- Treatment distance
- Thermal performance
- Safety features
- Clinical evidence [1,2]
How to Evaluate a Neonatal Phototherapy Device for a NICU
Selecting a neonatal phototherapy device should involve more than comparing LED specifications. A practical evaluation should include the following.
1. Spectral Quality and Irradiance
Ask the manufacturer:
- What wavelength range does the device emit?
- What is the peak wavelength?
- What irradiance is delivered at the infant’s skin?
- At what treatment distance is the irradiance measured?
- How is irradiance measured?
- Which radiometer is recommended?
- How uniform is the irradiance across the treatment area?
The AAP emphasizes that irradiance measurements should be performed using an appropriate meter calibrated for the wavelength range delivered by the phototherapy system. [2]
2. Illuminated Body Surface Area
The amount of infant skin receiving therapeutic light is an important component of intensive phototherapy. [1,2]
A device that produces high irradiance over a small area may not provide the same treatment geometry as a system designed to illuminate a larger proportion of the infant’s body surface. For this reason, procurement teams should evaluate both irradiance and light footprint.
3. Irradiance Uniformity
Peak irradiance alone does not describe the entire treatment field. Ask for irradiance measurements across the treatment area rather than a single central reading.
A useful evaluation should consider:
- Center irradiance
- Peripheral irradiance
- Treatment-area distribution
- Measurement distance
- Measurement method
This provides a more meaningful picture of the light dose delivered across the infant’s exposed body surface.
4. Safety and Thermal Management
Phototherapy systems should be evaluated for:
- Eye protection requirements
- Thermal performance
- Accessibility for nursing care
- Electrical safety
- Cleaning and infection-control requirements
- Mechanical stability
- Alarm and monitoring functions where applicable
The AAP also emphasizes attention to ambient temperature and device configuration to reduce the risk of hypothermia or hyperthermia during treatment. [2]
5. Clinical Evidence
Ask manufacturers to provide evidence supporting their clinical claims. Useful documentation may include:
- Peer-reviewed clinical studies
- Bilirubin reduction data
- Treatment-duration data
- Exchange-transfusion outcomes
- Irradiance measurements
- Data on the specific device configuration
- Study population and inclusion criteria
- Treatment protocols
- Measurement methods
Importantly, laboratory specifications and clinical outcomes are related but are not interchangeable. The AAP notes that in-vitro photodegradation results do not necessarily predict clinical effectiveness because bilirubin production, elimination, infant skin characteristics, and other clinical variables affect treatment response. [2]
6. Reliability and Total Cost of Ownership
Procurement teams should also consider:
- LED operating life
- Calibration requirements
- Preventive maintenance
- Cleaning and disinfection
- Replacement components
- Energy consumption
- Warranty
- Technical support
- Local service availability
- Regulatory documentation
A lower purchase price does not necessarily result in a lower total cost of ownership.
Supporting Efficient Phototherapy and Parent–Infant Care
Effective phototherapy is not simply about maximizing light intensity. The clinical objective is to deliver an appropriate therapeutic dose safely while monitoring the infant’s bilirubin response and clinical condition.
Treatment interruptions should be minimized when clinically appropriate, while feeding, nursing care, and appropriate parent–infant interaction remain important considerations. [1,2]
Device design can influence how easily clinicians can access the infant during phototherapy and how the treatment environment supports routine neonatal care. The AAP’s 2024 technical report identifies parent–infant bonding and device design as areas that should be considered alongside phototherapy effectiveness and safety. [2]
Why Device Design Matters in Intensive Phototherapy
Two systems may both be described as “LED phototherapy,” yet their clinical characteristics can differ substantially. Important variables include:
- Wavelength
- Spectral bandwidth
- Irradiance
- Irradiance uniformity
- Light footprint
- Exposed body surface area
- Distance from the light source
- Thermal management
- Measurement method
- Clinical evidence [1,2]
This is why hospitals should evaluate phototherapy systems using measurable specifications and clinical evidence rather than relying solely on the type of light source.
Bilisphere 360: Clinical Evidence for Multidirectional Phototherapy
The Bilisphere 360 LED is a multidirectional intensive phototherapy system designed to deliver therapeutic light around the newborn.
Clinical research has evaluated Bilisphere 360 in newborns receiving intensive phototherapy. A prospective study conducted at Cairo University Paediatric Hospital included 360 newborns with indirect hyperbilirubinemia. Of these, 183 newborns received Bilisphere 360, while 177 historical controls received conventional phototherapy. [3]
In that study population, the Bilisphere 360 group had a significantly shorter mean duration of phototherapy:
- 2.7 days with Bilisphere 360
- 4.2 days with conventional phototherapy [3]
The proportion of newborns requiring exchange transfusion was also lower in the Bilisphere 360 group:
- 10.4% in the Bilisphere 360 group
- 73.4% in the historical control group [3]
The reported differences were statistically significant. [3]
However, the study used historical controls rather than randomized concurrent controls. The historical control group had been treated before the Bilisphere 360 group, and the study therefore cannot establish the same level of causal certainty as a randomized controlled trial. These findings should be interpreted in the context of the study design, patient population, treatment protocol, and clinical setting rather than as a guarantee of outcomes for every newborn. [3]
NOVOS clinical materials report bilirubin reduction with Bilisphere 360 of up to approximately 0.84 mg/dL per hour. This should be understood as a manufacturer-reported clinical performance value, not as a guaranteed rate for every patient. [4]
Individual bilirubin kinetics can vary according to:
- Gestational age
- Baseline bilirubin level
- Underlying cause of hyperbilirubinemia
- Hemolysis
- Treatment conditions
- Feeding and hydration
- Clinical status
For clinicians and procurement teams, this distinction is important: device performance data should always be interpreted according to the patient population, treatment protocol, measurement method, study design, and source of the reported data.
Practical Checklist for Comparing Neonatal Phototherapy Devices
Before purchasing an intensive neonatal phototherapy system, ask each supplier to provide:
- Peak wavelength and spectral output
- Effective spectral irradiance in µW/cm²/nm
- Irradiance measurement method
- Recommended irradiance meter
- Irradiance distribution across the treatment area
- Maximum illuminated body surface area
- Treatment distance and geometry
- Clinical evidence supporting bilirubin reduction
- Published treatment-duration data, where available
- Evidence relating specifically to the device configuration
- LED lifetime
- Thermal-management specifications
- Cleaning and infection-control instructions
- Calibration and maintenance requirements
- Applicable regulatory certifications and declarations
- Quality-management certification such as ISO 13485, where applicable
- Warranty and technical-service information
- Local service and distributor support
This approach allows NICUs to compare devices using objective clinical and technical criteria rather than relying primarily on marketing claims.
Conclusion
Neonatal jaundice is common, but significant hyperbilirubinemia requires appropriate assessment and timely treatment. [1,2]
Phototherapy remains a cornerstone of neonatal hyperbilirubinemia management. Modern intensive phototherapy systems use therapeutic blue-to-green light, controlled irradiance, and optimized exposure of the infant’s body surface to accelerate bilirubin photoconversion. [1,2]
For NICUs evaluating phototherapy equipment, the most important question is not simply whether a system uses LEDs. The evaluation should include:
- Spectral quality
- Effective irradiance
- Irradiance uniformity
- Illuminated body surface area
- Thermal management
- Safety
- Clinical evidence
- Reliability
- Total cost of ownership
Bilisphere 360 represents NOVOS Medical Systems‘ multidirectional approach to intensive neonatal phototherapy. Published research has evaluated the system in newborns with indirect hyperbilirubinemia and reported shorter phototherapy duration and fewer exchange transfusions compared with historical conventional-phototherapy controls. These findings should be interpreted according to the study design and clinical population. [3]
Ultimately, effective phototherapy depends on the interaction between the device, the delivered light dose, the exposed body surface, and the clinical characteristics of the infant.
FAQ — Neonatal Phototherapy
How does phototherapy reduce bilirubin in newborns?
Phototherapy exposes the newborn’s skin to therapeutic blue-to-green light. The light induces photochemical changes in unconjugated bilirubin, producing photoisomers and other photoproducts that can be eliminated more readily from the body. [2]
What is intensive phototherapy?
Intensive phototherapy uses therapeutic blue light at an adequate irradiance while exposing as much of the infant’s body surface as practical. The AAP recommends intensive phototherapy using narrow-spectrum LED blue light with irradiance of at least approximately 30 µW/cm²/nm in term infants, with treatment decisions based on the applicable bilirubin threshold and clinical risk factors. [1,2]
What wavelength is used for neonatal phototherapy?
The AAP’s 2024 technical report identifies approximately 460–490 nm as the relevant blue-to-green range, with an optimal peak around 478 nm. [2]
What irradiance is recommended for intensive phototherapy?
For term infants, the AAP recommends an irradiance of at least approximately 30 µW/cm²/nm for intensive phototherapy, with appropriate measurement using an irradiance meter suited to the device and wavelength range. [1,2]
Is LED phototherapy better than fluorescent phototherapy?
LED systems can provide precise spectral output, long operating life, and favorable thermal and maintenance characteristics. However, clinical effectiveness depends on the complete device configuration, including spectral irradiance, treatment area, irradiance uniformity, and clinical performance. LED technology alone does not guarantee superior treatment. [1,2]
What is the difference between overhead and multidirectional phototherapy?
Overhead phototherapy primarily delivers light from above the infant. Multidirectional phototherapy delivers therapeutic light from multiple directions and may increase the proportion of the infant’s body surface receiving therapeutic light. The AAP emphasizes maximizing exposed body surface area during effective intensive phototherapy. [1,2]
How fast can Bilisphere 360 reduce bilirubin?
NOVOS reports bilirubin reduction with Bilisphere 360 of up to approximately 0.84 mg/dL per hour. This is a manufacturer-reported performance figure and should not be interpreted as a guaranteed rate for every newborn. Treatment response depends on the infant’s clinical characteristics, underlying cause of hyperbilirubinemia, bilirubin production rate, and treatment conditions. [4]
Can phototherapy prevent exchange transfusion?
Effective phototherapy can reduce bilirubin concentrations and may reduce the likelihood that an infant reaches a threshold requiring escalation of care, including exchange transfusion. [1,2]
In one prospective study with historical controls, Bilisphere 360 was associated with a lower proportion of exchange transfusions than conventional phototherapy in the study population. However, phototherapy does not eliminate the need for exchange transfusion in every clinical situation, and the study design limits how broadly the results can be generalized. [3]
How is phototherapy effectiveness measured?
Phototherapy effectiveness can be evaluated using the infant’s bilirubin response together with technical characteristics such as spectral irradiance, irradiance distribution, treatment footprint, and exposed body surface area. [1,2]
Appropriate irradiance measurement is important because different meters can produce different readings depending on calibration, spectral response, and measurement geometry. [2]
What should hospitals consider when selecting a neonatal phototherapy device?
Hospitals should evaluate wavelength, spectral irradiance, irradiance uniformity, exposed body surface area, treatment geometry, thermal performance, safety, clinical evidence, maintenance requirements, regulatory documentation, and total cost of ownership.
About NOVOS Medical Systems
NOVOS Medical Systems develops neonatal intensive-care equipment, including phototherapy systems designed for different clinical environments. Its neonatal portfolio includes the Bilisphere 360 LED multidirectional intensive phototherapy system and other neonatal phototherapy solutions.
Learn more about the Bilisphere 360 multidirectional intensive phototherapy system, its treatment configuration, technical features, and clinical evidence.
Download the Bilisphere 360 Brochure →
Review technical specifications, treatment configuration, and product information for clinical and procurement evaluation.
Contact NOVOS / Find a Local Distributor →
Contact NOVOS Medical Systems for product information, technical documentation, distributor support, or procurement inquiries.
References
- Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022;150(3):e2022058859.
- American Academy of Pediatrics. Phototherapy to Prevent Severe Neonatal Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation: Technical Report. Pediatrics. 2024;154(3):e2024068026.
- Edris AAF, Abdel Ghany EG, Abdel Razek AA, Zahran AM. The role of intensive phototherapy in decreasing the need for exchange transfusion in neonatal jaundice. J Pak Med Assoc. 2014;64(1):5–8. PMID: 24605703.
- NOVOS Medical Systems. Bilisphere 360 LED clinical and product information. Manufacturer-reported data.
Disclaimer
This article is intended for general clinical education and medical-device procurement guidance. It is not a substitute for professional medical judgment, institutional protocols, applicable clinical guidelines, or the manufacturer’s official instructions for use.
Phototherapy should be administered according to the infant’s clinical condition, applicable guidelines, hospital protocols, and the manufacturer’s instructions for use.
Device specifications, regulatory status, certifications, and clinical performance claims should be verified against current official product documentation before procurement or clinical use.
